REGENERATIVE MEDICINE

INTRADISCAL PRP STUDY

BACKGROUND: Low back pain is the number one cause of musculoskeletal disability world-wide.  Neck pain, although less prevalent than back pain, is attributed to similar causes.  Disc degeneration starts with a tear of the annulus fibrosus that can result in acute and chronic pain and progress to disc herniation and degeneration.   We have experienced success with disc injections of platelet-rich plasma (PRP) to augment the natural healing response. The  technique and rationale can be found in “Platelet Rich Plasma”, editor Lana, publisher Springer, 2014.

HYPOTHESIS: We hypothesize that injections of Platelet-Rich Plasma (PRP) will deliver the best outcomes for patients who obtain a positive response to an anesthetic discogram, who have a history of an acute injury to their disc or findings of annular tear, and who have lower risk factors for ongoing disc degeneration.

Platelet-Rich Plasma is a biologic agent derived from a patient’s own blood, containing concentrations of platelets ranging from 2.5 to over 20 times than in blood, with and without white blood cells. PRP is injected directly into the affected area to deliver potent growth factors often in areas where the blood supply is depleted. The platelets activate and form a sticky fibrin matrix, secrete growth factors and recruit stem cells to promote healing.

CURRENT RESEARCH FINDINGS: As of January 2018, Dr. Bodor has delivered intradiscal PRP to 245 patients, treating 589 discs – including cervical, thoracic, and lumbar – through a total of 296 procedures. Approximately 75% of patients have experienced good to excellent outcomes in 6 – 8 weeks following the injections. Dr. Bodor and his research team will complete a three-month and a one-year follow up with those who have received PRP treatment for degenerative disc disease.

GOAL: We hope to establish the efficacy of similar PRP injection in the cervical spine and will continue to prove the effectiveness on the lumbar and thoracic spine for eventual publication.

PILOT STUDY: Bone Marrow Aspirate Concentrate

BACKGROUND: We are tracking outcomes in a patient who received BMAC treatment for a rupture of his ACL in his knee. At 6 months, post-procedure a MRI performed by the same equipment and verified by two radiologists, showed evidence of complete healing of the anteromedial bundle of the ACl. A follow up MRI will be taken at one year to ensure durability of the repair.

Bone Marrow Aspirate Concentrate (BMAC) functions as a factory for platelets, red blood cells and white blood cells. it also contains small concentrations of mesenchymal stem cells. In the lab, these can be transformed into muscle, tendon, ligament, cartilage, and bone cells.  Injected into arthritic joints, degenerating tendons and torn ligaments, concentrated bone marrow can reduce inflammation and stimulate growth and repair.

GOAL: To heal the posterolateral bundle of the ACL with a second procedure.

PROSPECTIVE STUDY: Tracy Hoeg, MD, PhD, and of the 2018-19 fellows joining Bodor Clinic will be working with us to develop a prospective study of Bone Marrow Concentrate for ACL tears, and will try to obtain IRB approval through UC Davis.

 Reduce Pain. Increase Mobility + Function. Improve Quality of Life.

All the research conducted through the Napa Medical Research Foundation, a 501(c)(3) nonprofit organization, is fully funded through generous donations received from individuals and family foundations.

Pin It on Pinterest

Share This